Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  Issue 500MedicationType 1 Diabetes

Approved Drug Slows Type 1 Diabetes

The drug rituximab already used to treat autoimmune disorders may also slow the destruction of insulin-producing cells in patients with insulin-dependent (Type 1) diabetes.

Advertisement

In Type 1 diabetes, formerly known as juvenile diabetes, insulin-producing beta cells in the pancreas are destroyed by an autoimmune process.

Researchers at University of Texas Southwestern and 14 other centers worldwide found that injections of the drug rituximab slowed beta cell destruction for at least a year in the pancreas of those newly diagnosed with Type 1 diabetes, suggesting a potential treatment option to improve management and reduce long-term complications of the disease.
 
The findings are extremely exciting says Dr. Philip Raskin, principal investigator and professor of internal medicine at UT Southwestern but adds,"Our findings in no way suggest that rituximab should be used as a treatment or that it will eliminate the need for daily insulin injections....This is not a cure for Type 1 diabetes."

Dr. Raskin went on the explain, "The results do, however, provide evidence that B cells play a significant role in Type 1 diabetes, and that selective suppression of these B cells may deter the destruction of the body's beta cells."
 
Prior research has shown that two types of immune cells -- B cells and T cells -- help trigger Type 1 diabetes. T cells attack and destroy the insulin-producing beta cells. The B cells, however, don't directly attack insulin-producing cells, but researchers have speculated that they trigger the T cells to attack. Rituximab directly attacks and destroys the B cells.
 
Researchers conducted a study in which 81 participants received infusions of either rituximab or a placebo once a week for four weeks. The participants ranged in age from 8 to 40 years old and had been diagnosed with Type 1 diabetes within 100 days of enrollment in the study. They returned approximately every three months for two years to undergo blood tests and meet with a physician. Two-thirds of the 81 participants received the drug.

After one year, the participants who received rituximab needed lower doses of insulin and were able to produce more of their own insulin than those who received the placebo. They also had better control of their blood sugar.

Dr. Raskin said researchers do not think rituximab could ever be used to completely reverse Type 1 diabetes because the pancreas typically is too damaged by the time diabetes is diagnosed.
 
He also said that while the exact mechanism of how rituximab affects Type 1 diabetes remains unclear, the study clearly shows that a therapy that targets B cells may improve beta-cell function in early Type 1 diabetes.

New England Journal of Medicine, December 4, 2009

 

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 15 December, 2009 and appeared in  Issue 500MedicationType 1 Diabetes

Past five issues: Diabetes Clinical Mastery Series Issue 256 | Issue 796 | Diabetes Clinical Mastery Series Issue 255 | Issue 795 | SGLT-2 Inhibitors Special Edition August 2015 |

2015 Most Popular Articles:

Coffee Consumption Proves Potential in Reducing Type 2 Diabetes Risk
Posted August 07, 2015
Ketoacidosis Not as Great as Thought in Diabetes Patients Taking Invokana
Posted August 13, 2015
Impaired Glucose Uptake in the Brain May Increase Alzheimer's Disease Risk
Posted August 07, 2015
Soybean Oil Causes More Obesity and Diabetes Than Fructose
Posted August 20, 2015
Impact of Switching Insulin Glargine to Insulin Detemir in T2 Patients
Posted August 14, 2015
First Non-Surgical Weight Loss Procedure for Mild-to-Moderate Obesity
Posted August 07, 2015
SIgnificant Weight Gain Associated with Laparoscopic Sleeve Gastrectomy
Posted August 14, 2015
What A Can of Coca-Cola Really Does To Your Body
Posted August 20, 2015
GLP-1 Agonist Semaglutide Completes Phase III Trial with Positive Results
Posted August 07, 2015
Diabetes Combination Drug LixiLan Meets Main Target in Late Stage Trial
Posted August 07, 2015


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
What percentage of your patients tests their postprandial blood sugars?